Literature DB >> 12759734

[Cutaneous leishmaniasis].

C D Enk1, K Gardlo, M Hochberg, A Ingber, T Ruzicka.   

Abstract

Leishmaniasis is a vector-borne disease caused by an obligate intracellular protozoa, Leishmania, which resides in macrophages. The parasite is transmitted by an infected female sandfly. The incidence of cutaneous leishmaniasis approaches 2 million new cases per year with 90% of the cases occurring in the "Old World", while the "New World" accounts for the rest. Infection may be restricted to the skin with development of characteristic ulcers, or may affect the mucous membranes in its mucocutaneous form. The clinical diagnosis is verified by the presence of amastigotes in slit-skin smears. Therapeutic modalities include systemic treatments such as the pentavalent antimony compound sodium stibogluconate, liposomal formulations of amphotericin B, oral ketoconazole or itraconazole, as well as topical paromomycin sulphate, local heat, freezing with liquid nitrogen, or photodynamic therapy. An effective vaccine is not available.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12759734     DOI: 10.1007/s00105-003-0530-5

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  35 in total

1.  Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.

Authors:  T K Jha; P Olliaro; C P Thakur; T P Kanyok; B L Singhania; I J Singh; N K Singh; S Akhoury; S Jha
Journal:  BMJ       Date:  1998-04-18

2.  Post-kala-azar dermal leishmaniasis occurring long after cure of visceral leishmaniasis in Kenya.

Authors:  J R Rashid; C N Chunge; C N Oster; K M Wasunna; R Muigai; G S Gachihi
Journal:  East Afr Med J       Date:  1986-05

Review 3.  Type 1 and type 2 responses to Leishmania major.

Authors:  Kathleen A Rogers; Gregory K DeKrey; M Lamine Mbow; R Dean Gillespie; Claudia I Brodskyn; Richard G Titus
Journal:  FEMS Microbiol Lett       Date:  2002-03-19       Impact factor: 2.742

Review 4.  Leishmaniasis.

Authors:  B L Herwaldt
Journal:  Lancet       Date:  1999-10-02       Impact factor: 79.321

5.  Terbinafine in the treatment of cutaneous leishmaniasis: a pilot study.

Authors:  K A Bahamdan; T M Tallab; H Johargi; M M Nourad; K Ibrahim; A H el Sherbini; E Karkashan; A K Khare; M M Nauri
Journal:  Int J Dermatol       Date:  1997-01       Impact factor: 2.736

Review 6.  Molecular biological applications in the diagnosis and control of leishmaniasis and parasite identification.

Authors:  Henk D F H Schallig; Linda Oskam
Journal:  Trop Med Int Health       Date:  2002-08       Impact factor: 2.622

Review 7.  The leishmaniases as model zoonoses.

Authors:  R W Ashford
Journal:  Ann Trop Med Parasitol       Date:  1997-10

8.  Treatment of cutaneous leishmaniasis by photodynamic therapy.

Authors:  Kerstin Gardlo; Zuzana Horska; Claes David Enk; Lucie Rauch; Mossad Megahed; Thomas Ruzicka; Clemens Fritsch
Journal:  J Am Acad Dermatol       Date:  2003-06       Impact factor: 11.527

9.  Cutaneous leishmaniasis in British troops from Belize.

Authors:  N C Hepburn; M J Tidman; J A Hunter
Journal:  Br J Dermatol       Date:  1993-01       Impact factor: 9.302

10.  Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala.

Authors:  T R Navin; B A Arana; F E Arana; J D Berman; J F Chajón
Journal:  J Infect Dis       Date:  1992-03       Impact factor: 5.226

View more
  5 in total

1.  [Topical treatment of persistent cutaneous leishmaniasis with paromomycin].

Authors:  M J Flaig; J Rupec; T Ruzicka; R A Rupec
Journal:  Hautarzt       Date:  2007-08       Impact factor: 0.751

2.  [Chronic lupoid leishmaniasis. A rare differential diagnosis in Germany for erythematous infiltrative facial plaques].

Authors:  A Herrmann; J Wohlrab; H Sudeck; G-D Burchard; W C Marsch
Journal:  Hautarzt       Date:  2007-03       Impact factor: 0.751

3.  [Photodynamic therapy of cutaneous leishmaniasis. A promising new therapeutic modality].

Authors:  K Gardlo; S Hanneken; T Ruzicka; N J Neumann
Journal:  Hautarzt       Date:  2004-04       Impact factor: 0.751

4.  In vitro and in vivo activities of Peganum harmala extract against Leishmania major.

Authors:  Parvaneh Rahimi-Moghaddam; Soltan Ahmed Ebrahimi; Hourmazd Ourmazdi; Monawar Selseleh; Maryam Karjalian; Giti Haj-Hassani; Mohammad Hossein Alimohammadian; Massoud Mahmoudian; Massoumeh Shafiei
Journal:  J Res Med Sci       Date:  2011-08       Impact factor: 1.852

5.  Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar).

Authors:  Viroj Wiwanitkit
Journal:  Ther Clin Risk Manag       Date:  2012-06-22       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.